Molbio’s Financials, Revenue, Profit, Valuation & Shareholding Overview (2025)

Molbio Diagnostics, co-founded by Chandrashekhar Nair, Sriram Natarajan, and Sangeetha Sriram, is a pioneering company in the field of molecular diagnostics. Founded in 2000 and headquartered in Goa, Molbio has transformed the diagnostics landscape with its innovative Truenat platform. This real-time PCR-based portable technology allows rapid and accurate detection of a wide range of infectious diseases directly at the point of care, making diagnostics more accessible and affordable, especially in remote and resource-limited settings. Molbio’s mission to democratize access to advanced diagnostics has helped tackle public health challenges by enabling early detection and timely treatment. The company has expanded its global footprint, providing solutions to over 40 countries and partnering with governments, NGOs, and health organizations. With a strong commitment to R&D, Molbio continually develops new test panels to address emerging diseases. Backed by leading investors and significant grant support, Molbio is poised for sustained growth and impact, reinforcing its position as a leader in affordable, decentralized diagnostics solutions worldwide.

Molbio Diagnostics has demonstrated strong revenue growth, scaling from around $60 million in FY22 to approximately $85 million in FY23, driven by its Truenat platform and global expansion. The company has maintained a positive net profit position, reflecting operational efficiency and robust demand for its rapid diagnostic solutions. This growth trajectory underscores Molbio’s leadership in decentralized and point-of-care diagnostics.

Molbio maintains strong cost controls, enabling sustained profitability even as expenses increase to support expansion and innovation. Margins are healthy, reflecting operational efficiencies and a robust business model.

Molbio’s workforce expanded from ~1,200 in FY22 to ~1,600 in FY24, strengthening capabilities in R&D, manufacturing, and global commercial operations. This reflects the company’s commitment to scaling access to affordable diagnostics.

• Expand Truenat adoption across emerging markets.
• Strengthen distribution networks and manufacturing capacity.
• Increase investment in new test panels and infectious disease solutions.
• Build strategic partnerships globally.
• Evaluate IPO readiness based on future growth opportunities.

Molbio continues to secure major partnerships and expand into new geographies, emphasizing rapid, decentralized testing. Recent funding and grants will support further innovation and access initiatives worldwide.

Company websites, media reports, and publicly available funding data.